Featured Publications
MIF is a common genetic determinant of COVID-19 symptomatic infection and severity
Shin JJ, Fan W, Par-Young J, Piecychna M, Leng L, Israni-Winger K, Qing H, Gu J, Zhao H, Schulz WL, Unlu S, Kuster J, Young G, Liu J, Ko AI, Garcia A, Sauler M, Wisnewski AV, Young L, Orduña A, Wang A, Klementina O, Garcia AB, Hegyi P, Armstrong ME, Mitchell P, Ordiz DB, Garami A, Kang I, Bucala R. MIF is a common genetic determinant of COVID-19 symptomatic infection and severity. QJM 2022, 116: 205-212. PMID: 36222594, PMCID: PMC9620729, DOI: 10.1093/qjmed/hcac234.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorLow-expression MIF alleleCOVID-19 infectionMIF allelesCATT7 alleleHealthy controlsCOVID-19Serum macrophage migration inhibitory factorSymptomatic SARS-CoV-2 infectionHigher serum MIF levelsHigh-expression MIF allelesRetrospective case-control studySARS-CoV-2 infectionFunctional polymorphismsAvailable clinical characteristicsMultinational retrospective studySerum MIF levelsUninfected healthy controlsSymptomatic COVID-19Tertiary medical centerHealthy control subjectsCase-control studyMigration inhibitory factorCoronavirus disease 2019Common functional polymorphisms
2024
Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma
Valdez C, Sánchez-Zuno G, Osmani L, Ibrahim W, Galan A, Bacchiocchi A, Halaban R, Kulkarni R, Kang I, Bucala R, Tran T. Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma. Oncotarget 2024, 15: 507-520. PMID: 39028303, PMCID: PMC11259151, DOI: 10.18632/oncotarget.28615.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Differentiation, B-LymphocyteBiomarkers, TumorFemaleHistocompatibility Antigens Class IIHumansImmune Checkpoint InhibitorsIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMaleMelanomaMiddle AgedMutationPrognosisRetrospective StudiesSkin NeoplasmsConceptsMacrophage migration inhibitory factorImmune checkpoint inhibitionD-dopachrome tautomeraseExpression of macrophage migration inhibitory factorDrivers of tumor progressionInflammatory cell markersPatient tumor samplesPatient survival outcomesMigration inhibitory factorStatistically significant differenceCheckpoint inhibitionImmune therapyPrognostic valueSurvival outcomesResistant melanomaGene expressionImproved survivalRetrospective studyInflammatory markersTumor progressionCell markersTumor samplesClinical evidenceMelanomaBulk RNA sequencing
2022
Clinical features and high-risk indicators of central nervous system involvement in primary Sjögren’s syndrome
Fan W, Par-Young J, Li K, Zhang Y, Xiao P, Hua L, Leng L, Chen X, Bucala R. Clinical features and high-risk indicators of central nervous system involvement in primary Sjögren’s syndrome. Clinical Rheumatology 2022, 42: 443-451. PMID: 36401063, PMCID: PMC9873757, DOI: 10.1007/s10067-022-06448-w.Peer-Reviewed Original ResearchMeSH KeywordsCentral Nervous SystemCentral Nervous System DiseasesHumansRetrospective StudiesRisk FactorsSjogren's SyndromeConceptsCentral nervous system involvementNervous system involvementPotential risk factorsPrimary Sjögren's syndrome patientsHigh-dose glucocorticoidsSjögren's syndrome patientsCNS involvementSystem involvementHigh-risk indicatorsImmunosuppressive therapyLung involvementSyndrome patientsC3 levelsRisk factorsPulmonary involvementPS patientsHigh-dose glucocorticoid administrationMultivariate logistic regression analysisAnti-SSA positivityHigh titer ANAAnti-SSA antibodiesLow C3 levelsPrimary Sjögren's syndromeComplement 4 levelsLogistic regression analysis
2001
URINE MACROPHAGE MIGRATION INHIBITORY FACTOR CONCENTRATIONS AS A DIAGNOSTIC TOOL IN HUMAN RENAL ALLOGRAFT REJECTION1
Brown F, Nikolic-Paterson D, Chadban S, Dowling J, Jose M, Metz C, Bucala R, Atkins R. URINE MACROPHAGE MIGRATION INHIBITORY FACTOR CONCENTRATIONS AS A DIAGNOSTIC TOOL IN HUMAN RENAL ALLOGRAFT REJECTION1. Transplantation 2001, 71: 1777-1783. PMID: 11455258, DOI: 10.1097/00007890-200106270-00013.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorAcute rejectionMIF concentrationsRenal transplant patientsCyA toxicityTransplant patientsProspective studyRetrospective studyNormal controlsSerum macrophage migration inhibitory factorUrine macrophage migration inhibitory factorAcute renal allograft rejectionStable renal transplant patientsDay 1 posttransplantationEpisodes of biopsyLocal MIF productionRenal allograft patientsRENAL ALLOGRAFT REJECTION1Renal transplant dysfunctionSerum MIF concentrationsSerum MIF levelsTransplant patient groupsRenal allograft rejectionPro-inflammatory cytokinesNormal healthy controls